MedTrace Logo

24-hour Study of Dorzolamide/Timolol and Latanoprost/Timolol Fixed Combinations

NCT00397241 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2020-12-19

No results posted yet for this study

Summary

The primary objective of this crossover trial is to compare the 3-month mean 24-hour intraocular pressure (IOP) control and safety of dorzolamide/timolol fixed combination (DTFC) given twice daily, versus latanoprost/timolol fixed combination (LTFC) given in the evening and placebo given in the morning, versus adjunctive therapy with DTFC given twice daily and latanoprost 0.005% given once in the evening in open-angle glaucoma patients who are insufficiently controlled with latanoprost monotherapy.

Conditions

  • Open-angle Glaucoma

Interventions

DRUG

Drug: dorzolamide/timolol

DRUG

Drug: latanoprost/timolol

DRUG

dorzolamide/timolol and latanoprost

DRUG

placebo (artificial tears)

Sponsors & Collaborators

  • Aristotle University Of Thessaloniki

    lead OTHER

Principal Investigators

  • Anastasios GP Konstas, MD, PhD · Glaucoma Unit, A University Department of Ophthalmology, AHEPA Hospital, Thessaloniki, Greece

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
29 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2007-12-31
Completion
2007-12-31

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00397241 on ClinicalTrials.gov